NovoRapid PumpCart (insulin aspart) - supply shortage
Ongoing
insulin aspart
ShortageHuman
Shortage information
There is a shortage of NovoRapid PumpCart in the EU/EAA (European Economic Area).
NovoRapid is used to treat adults, adolescents and children over one year old who have diabetes. It contains the active substance insulin aspart, a fast-acting insulin. The NovoRapid PumpCart is one of the presentations of this medicine.
For further information on the use of the medicine please refer to the medicine’s overview page.
The current manufacturing capacity for NovoRapid PumpCart cannot meet demand. This has led or may lead to intermittent shortages of NovoRapid PumpCart. The shortages are not related to a quality defect of the product or a safety issue.
All Member States where the product is marketed are currently affected or are at risk of being affected by the intermittent shortages: Austria, Belgium, Czechia, Denmark, Finland, France, Germany, Italy, Luxembourg, Netherlands, Norway, Portugal, Slovakia, Slovenia, Spain and Sweden.
For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.
EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and EMA’s shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party) are closely monitoring the supply situation and engaging with the marketing authorisation holder and other stakeholders to mitigate the impact of the supply shortage.
- No new patients should be started on NovoRapid PumpCart throughout 2025.
- In case NovoRapid PumpCart is unavailable, healthcare professionals should switch existing patients to alternative fast-acting insulin therapy based on existing guidance and clinical judgment. Other fast-acting insulins include:
- NovoRapid, Fiasp or insulin aspart biosimilars;
- Insulin lispro or its biosimilars;
- Insulin glulisine or its biosimilars;
- Healthcare professionals should ensure that all patients are counselled on any changes and provided with adequate training
- A medicine shortage communication (MSC) has been sent to healthcare professionals in affected Member States and will also be published on the EMA website.
- For additional information, consult your country’s shortage register or contact your national competent authority.
- Contact your healthcare professional well before your current supply runs out.
- If you use NovoRapid PumpCart regularly, your healthcare professional will discuss an alternative insulin medicine with you.
- Your healthcare professional will ensure that you are counselled on any changes and provided with adequate training.
- If you have any questions, speak to your doctor or pharmacist.
- For additional information, consult your country’s shortage register or contact your national competent authority.
Key facts
- Medicines affected
- NovoRapid PumpCart (insulin aspart)
- Supply shortage status
- Ongoing
- International non-proprietary name (INN) or common name
- insulin aspart
- Pharmaceutical forms affected
- Solution for injection in a cartridge
- Strengths affected
- 100 units/mL
- Availability of alternatives
- Yes
Key dates
- Start of supply shortage
- First published